CAMBRIDGE, Mass.--(BUSINESS WIRE)--GenePeeks, Inc., a computational genomics company focused on transforming genetic disease risk analysis, today announced the appointment of Matt Posard as President and Chief Commercial Officer (CCO). Posard joins the team with more than 25 years of experience successfully commercializing innovative technologies in the life science and molecular diagnostics fields.
“We are thrilled to welcome Matt to our executive team. As President and CCO, he will lead commercialization of our next-generation products and services,” said Anne Morriss, Co-founder and Chief Executive Officer of GenePeeks. “Matt is an exceptional leader, with an incredible track record of building markets and accelerating adoption of transformative technologies. He will advance our mission to harness the full power and promise of modern genomics to help patients protect their future families.”
Over the course of his career, Posard has held influential leadership roles at a number of market leading companies including Illumina, Inc., Trovagene, Inc. and Alere, Inc. During his nine years at Illumina, Posard held several key executive positions including senior leadership roles in Marketing, Global Sales, Translational and Consumer Genomics, and New and Emerging Markets. He built and led the team responsible for growing company sales to more than $1 billion in five years, drove global product launches of multiple clinical and consumer genomic applications, and established several new business units where he oversaw Commercial, Product Development, Business Development, Professional Services and Laboratory Operations. He earned his Bachelor of Arts degree in Quantitative Economics and Decision Science from the University of California, San Diego.
“I am thrilled to be joining GenePeeks as the company enters an important growth phase,” said Matt Posard. “I was particularly drawn to the company’s unique technology and unrelenting passion to better protect our families, at the earliest possible point in the parenting journey. I look forward to working with this talented team and our growing network of clinician partners to help parents reduce their risk for passing on serious diseases.”
GenePeeks’ unique technology allows the company to computationally predict the genetic risk profile of a future child by using a patented, comprehensive approach called Virtual Progeny Analytics. The Company’s proprietary platform digitally combines genetic information from two prospective parents to generate and analyze thousands of potential genetic combinations—enabling high-resolution visibility into the risk of conceiving a child with more than 1,000 heritable diseases.
GenePeeks is a computational genomics company focused on identifying inherited disease risk in future generations. GenePeeks’ patented technology digitally combines the genetic information of two potential parents, simulating the complex genetic interactions that occur naturally in human reproduction. The company’s proprietary platform creates and analyzes thousands of Virtual Progeny to uncover disease risk that cannot be seen with alternative screening tools. GenePeeks offers physician-ordered testing and analytics performed in its clinical laboratory.
GenePeeks was founded by Chief Executive Officer, Anne Morriss, and Chief Science Officer, Lee Silver, Ph.D., Professor of Molecular Biology at Princeton University, to help families protect their future children from serious diseases. The company’s Executive Chair is Mara Aspinall, former Chief Executive Officer of Ventana Medical Systems and former President of Genzyme Genetics. GenePeeks is privately held, with corporate offices in Cambridge, Mass. For more information, visit www.genepeeks.com.
GenePeeks’ next-generation screening technology is available today. For more information about becoming a partner, please contact email@example.com.